181 related articles for article (PubMed ID: 36369677)
1. Evaluation of treosulfan cumulative exposure in paediatric patients through population pharmacokinetics and dosing simulations.
Rosser SPA; Lee S; Kohli S; Keogh SJ; Chung J; O'Brien T; Fraser C; McLachlan AJ; Shaw PJ; Nath CE
Br J Clin Pharmacol; 2023 Apr; 89(4):1413-1424. PubMed ID: 36369677
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of treosulfan in paediatric patients undergoing hematopoietic stem cell transplantation.
van der Stoep MYEC; Zwaveling J; Bertaina A; Locatelli F; Guchelaar HJ; Lankester AC; Moes DJAR
Br J Clin Pharmacol; 2019 Sep; 85(9):2033-2044. PubMed ID: 31144349
[TBL] [Abstract][Full Text] [Related]
3. Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing.
Bartelink IH; Boelens JJ; Bredius RG; Egberts AC; Wang C; Bierings MB; Shaw PJ; Nath CE; Hempel G; Zwaveling J; Danhof M; Knibbe CA
Clin Pharmacokinet; 2012 May; 51(5):331-45. PubMed ID: 22455797
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of treosulfan in pediatric patients undergoing hematopoietic stem cell transplantation.
Ten Brink MH; Ackaert O; Zwaveling J; Bredius RG; Smiers FJ; den Hartigh J; Lankester AC; Guchelaar HJ
Ther Drug Monit; 2014 Aug; 36(4):465-72. PubMed ID: 24487253
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children.
Trame MN; Bergstrand M; Karlsson MO; Boos J; Hempel G
Clin Cancer Res; 2011 Nov; 17(21):6867-77. PubMed ID: 21918171
[TBL] [Abstract][Full Text] [Related]
6. Impact of Treosulfan Exposure on Early and Long-Term Clinical Outcomes in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients: A Prospective Multicenter Study.
van der Stoep MYEC; Bertaina A; Moes DJAR; Algeri M; Bredius RGM; Smiers FJW; Berghuis D; Buddingh EP; Mohseny AB; Guchelaar HJ; Locatelli F; Zwaveling J; Lankester AC
Transplant Cell Ther; 2022 Feb; 28(2):99.e1-99.e7. PubMed ID: 34607071
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetic modeling of treosulfan and rationale for dose recommendation in children treated for conditioning prior to allogeneic hematopoietic stem cell transplantation.
Li X; Kalwak K; Beier R; Kehne J; Möller AK; Baumgart J; Beelen DW; Hilger RA; Vora A; Sykora KW
Drug Metab Pharmacokinet; 2023 Oct; 52():100515. PubMed ID: 37481830
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic haematopoietic SCT.
Główka FK; Karaźniewicz-Łada M; Grund G; Wróbel T; Wachowiak J
Bone Marrow Transplant; 2008 Oct; 42 Suppl 2():S67-70. PubMed ID: 18978748
[TBL] [Abstract][Full Text] [Related]
9. High interpatient variability of treosulfan exposure is associated with early toxicity in paediatric HSCT: a prospective multicentre study.
van der Stoep MYEC; Bertaina A; Ten Brink MH; Bredius RG; Smiers FJ; Wanders DCM; Moes DJAR; Locatelli F; Guchelaar HJ; Zwaveling J; Lankester AC
Br J Haematol; 2017 Dec; 179(5):772-780. PubMed ID: 29048102
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic behavior and appraisal of intravenous busulfan dosing in infants and older children: the results of a population pharmacokinetic study from a large pediatric cohort undergoing hematopoietic stem-cell transplantation.
Paci A; Vassal G; Moshous D; Dalle JH; Bleyzac N; Neven B; Galambrun C; Kemmel V; Abdi ZD; Broutin S; Pétain A; Nguyen L
Ther Drug Monit; 2012 Apr; 34(2):198-208. PubMed ID: 22406655
[TBL] [Abstract][Full Text] [Related]
11. Model-informed precision dosing for alemtuzumab in paediatric and young adult patients undergoing allogeneic haematopoietic cell transplantation.
Dong M; Emoto C; Fukuda T; Arnold DE; Mehta PA; Marsh RA; Vinks AA
Br J Clin Pharmacol; 2022 Jan; 88(1):248-259. PubMed ID: 34182590
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Dose Adjustment Strategies for Obesity in High-dose Cyclophosphamide Among Adult Hematopoietic Cell Transplantation Recipients: Pharmacokinetic Analysis.
Takahashi T; Jaber MM; Al-Kofahi M; Weisdorf D; Brunstein C; Bachanova V; Brundage RC; Jacobson PA; Kirstein MN
Transplant Cell Ther; 2022 Dec; 28(12):845.e1-845.e8. PubMed ID: 36167308
[TBL] [Abstract][Full Text] [Related]
13. Modelling of neutrophil dynamics in children receiving busulfan or treosulfan for haematopoietic stem cell transplant conditioning.
Solans BP; Chiesa R; Doncheva B; Prunty H; Veys P; Trocóniz IF; Standing JF
Br J Clin Pharmacol; 2020 Aug; 86(8):1537-1549. PubMed ID: 32077123
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of vancomycin and AUC-guided dosing in Chinese neonates and young infants.
Chen Y; Wu D; Dong M; Zhu Y; Lu J; Li X; Chen C; Li Z
Eur J Clin Pharmacol; 2018 Jul; 74(7):921-930. PubMed ID: 29602981
[TBL] [Abstract][Full Text] [Related]
15. Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium.
Nemecek ER; Hilger RA; Adams A; Shaw BE; Kiefer D; Le-Rademacher J; Levine JE; Yanik G; Leung W; Talano JA; Haut P; Delgado D; Kapoor N; Petrovic A; Adams R; Hanna R; Rangarajan H; Dalal J; Chewning J; Verneris MR; Epstein S; Burroughs L; Perez-Albuerne ED; Pulsipher MA; Delaney C
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1651-1656. PubMed ID: 29753157
[TBL] [Abstract][Full Text] [Related]
16. Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once-daily intravenous busulfan dosing nomogram.
Rhee SJ; Lee JW; Yu KS; Hong KT; Choi JY; Hong CR; Park KD; Shin HY; Song SH; Kang HJ; Lee H
Am J Hematol; 2017 Jul; 92(7):607-613. PubMed ID: 28370238
[TBL] [Abstract][Full Text] [Related]
17. Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: Results from a multicenter population pharmacokinetic study.
Ben Hassine K; Nava T; Théoret Y; Nath CE; Daali Y; Kassir N; Lewis V; Bredius RGM; Shaw PJ; Bittencourt H; Krajinovic M; Uppugunduri CRS; Ansari M
CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):1043-1056. PubMed ID: 34453497
[TBL] [Abstract][Full Text] [Related]
18. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis.
Bartelink IH; Lalmohamed A; van Reij EM; Dvorak CC; Savic RM; Zwaveling J; Bredius RG; Egberts AC; Bierings M; Kletzel M; Shaw PJ; Nath CE; Hempel G; Ansari M; Krajinovic M; Théorêt Y; Duval M; Keizer RJ; Bittencourt H; Hassan M; Güngör T; Wynn RF; Veys P; Cuvelier GD; Marktel S; Chiesa R; Cowan MJ; Slatter MA; Stricherz MK; Jennissen C; Long-Boyle JR; Boelens JJ
Lancet Haematol; 2016 Nov; 3(11):e526-e536. PubMed ID: 27746112
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of treosulfan and development of a limited sampling strategy in children prior to hematopoietic stem cell transplantation.
Danielak D; Twardosz J; Kasprzyk A; Wachowiak J; Kałwak K; Główka F
Eur J Clin Pharmacol; 2018 Jan; 74(1):79-89. PubMed ID: 28975382
[TBL] [Abstract][Full Text] [Related]
20. Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis--a population pharmacokinetic study.
Hennig S; Norris R; Kirkpatrick CM
Br J Clin Pharmacol; 2008 Apr; 65(4):502-10. PubMed ID: 17995972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
